Position paper “RSV in preterm and ill infants” makes a strong case for preventive measures to reduce the number of RSV infections
Respiratory Syncytial Virus is a virus that causes infections of the lungs and airways. It commonly appears during the coldest and wettest months of the year, similarly to the influenza virus. In adults and older children the symptoms are commonly mild, with cold-like symptoms such as rhinitis or coughing.
However, if more vulnerable patients (e.g. preterm infants, ill infants or elderly people) are infected with the virus, they may develop a severe lower respiratory tract infection, such as bronchiolitis or pneumonia. These complications often result in admission to a hospital or to the neonatal intensive care unit and sometimes in the use of mechanical ventilation. In particular, preterm infants and infants with bronchopulmonary dysplasia and haemodynamically significant congenital heart disease have an increased risk of severe RSV infections requiring hospitalisation.
There is no vaccination and no curative treatment available. The most effective method to prevent RSV infections in infants and young children are simple hygiene and behavioural measures. In addition, in some cases, immunoprophylaxis with palivizumab can be an option, as it has shown to be safe and effective and can be considered in high-risk infants during RSV season.
Expert roundtable – the starting point for the position paper
On the initiative of EFCNI, a high-ranking panel of medical and patient experts met in Munich on 17 October 2018 to discuss the challenges of RSV-related infections in preterm and ill infants in different countries, and the measures that are taken on a national level to improve the infection and hospitalisation rates. After a day of fruitful discussions, the key points for improvement were identified and agreed upon. The position paper was developed and finalised in August 2019 and was officially launched at the EFCNI lunch symposium “How can we protect preterm infants from RSV infections?” on 19 September 2019 at the 3rd Congress of joint European Neonatal Societies (jENS) in Maastricht. In December 2020 an updated version was re-launched including an extended list of prophylaxis guidelines from 33 countries.
The following experts and representatives of parent organisations were part of the panel (in alphabetical order):
Professor Angelika Berger, Medical University Vienna, Vienna, Austria; Professor Maria K. Borszewska-Kornacka, Medical University Warsaw, Warsaw, Poland; Mandy Daly, Irish Neonatal Health Alliance (INHA), Wicklow, Ireland; Professor Egbert Herting, University Hospital Schleswig-Holstein, Lübeck, Germany; Dr Paolo Manzoni, Division of Paediatrics, Department of Maternal, Neonatal and Infant Medicine, Nuovo Ospedale degli Infermi, ASL Biella, Biella, Italy; Associate Professor Fabio Midulla, Sapienza University, Rome, Italy; Professor Christian F. Poets, University of Tübingen, Tübingen, Germany; Professor Charles Christoph Roehr, University of Oxford, Oxford, UK; Professor Elie Saliba, Francois Rabelais University, Tours, France; Professor Manuel Sánchez Luna, University Hospital Gregorio Marañón, Madrid, Spain; Dr Renate Swarte, Erasmus MC-Sophia, Rotterdam, The Netherlands; Dr Miklós Szabó, Children‘s Hospital Semmelweis University, Budapest, Hungary; Dr Eleni Vavouraki, Ilitominon, Athens, Greece; Professor Sven Wellmann, University Children’s Hospital Regensburg, Regensburg, Germany; Professor Luc Zimmermann, Maastricht UMC+, Maastricht, The Netherlands.
EFCNI was represented by (in alphabetical order) :
Simone Cramer, Silke Mader, Dr Johanna Pfeil, Christine Schwaiger
Common call to action agreed to by all panel experts
The panel calls on all stakeholders involved in neonatal and paediatric research and care:
- To educate and train healthcare providers, parent representatives and policymakers about the risks associated with RSV infections, the risk factors for a severe course, and the measures of prevention and prophylaxis to reduce morbidity and hospitalisation in preterm and ill infants
- To develop a European-wide guideline on prevention, prophylaxis, supportive care measures and follow-up of RSV infections in preterm and ill infants, and to implement this European guideline on a national and local level
- To increase research efforts to collect more reliable follow-up data to understand the underlying mechanisms of RSV infections, and why they might cause respiratory problems later in life
- To increase efforts to develop a vaccine against RSV
- To provide accurate and reliable information to parents and families on RSV, including how they can reduce the risk of infection by following simple hygiene and behavioural rules
Interview with Professor Luc Zimmermann on RSV in preterm babies
Professor Luc J.I. Zimmermann is Professor of Paediatrics and Neonatology at Maastricht UMC+ in the Netherlands and Member of the Trustee Board of EFCNI. In this interview he explains:
- How a typical course of infection with RSV looks like
- Why preterm and ill babies are more at risk for serious complications from RSV infections
- How important hygiene measures are to prevent an infection
- In what cases the administration of the prophylactic drug palivizumab makes sense
RSV Factsheet: All you need to know about RSV in a nutshell
If you would like to get a quick overview of RSV, download our factsheet! Here you can learn e.g. which group of children is at risk for a more severe RSV infection, what are the most important risk factors, how is the virus transmitted, and what simple hygiene rules can largely reduce the risk of infection.
Go to download section
Social media graphics
Help protect babies from RSV and support RSV awareness by downloading our social media graphics and sharing them on your account. Tag us @efcni (Facebook/Instagram) and @EFCNIwecare (Twitter) and use #LittleLungs #RSV
We warmly thank the following healthcare societies and organisations for supporting the positionpaper on respiratory syncytial virus (RSV) in preterm and ill infants (in alphabetical order):
We warmly thank the following parent organisations for supporting the position paper on respiratory syncytial virus (RSV) in preterm and ill infants (in alphabetical order):
The topic “Respiratory syncyial virus (RSV)” is supported by AbbVie.